{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:46Z","timestamp":1793755066341,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T00:00:00Z","timestamp":1429747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40265-015-0398-6","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T02:55:56Z","timestamp":1429671356000},"page":"817-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Isavuconazonium: First Global Approval"],"prefix":"10.1007","volume":"75","author":[{"given":"Paul L.","family":"McCormack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,23]]},"reference":[{"key":"398_CR1","first-page":"163","volume":"6","author":"DR Falci","year":"2013","unstructured":"Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163\u201374.","journal-title":"Infect Drug Resist."},{"key":"398_CR2","unstructured":"US Food and Drug Administration. FDA approves new antifungal drug Cresemba. 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm437106.htm . Accessed 12 Mar 2015."},{"key":"398_CR3","unstructured":"US Food and Drug Administration. Cresemba (isavuconazonium sulfate): US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207500Orig1s000lbl.pdf . Accessed 18 Mar 2015."},{"key":"398_CR4","unstructured":"Astellas Pharma US Inc. FDA grants Astellas Qualified Infectious Disease Product designation for isavuconazole for the treatment of invasive candidiasis (media release). 2014. http:\/\/newsroom.astellas.us\/2014-07-16-FDA-Grants-Astellas-Qualified-Infectious-Disease-Product-Designation-for-Isavuconazole-for-the-Treatment-of-Invasive-Candidiasis ."},{"key":"398_CR5","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: isavuconazonium sulfate for the treatment of invasive aspergillosis. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2014\/07\/WC500169890.pdf . Accessed 18 Mar 2015."},{"key":"398_CR6","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: isavuconazonium sulfate for the treatment of mucormycosis. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2014\/07\/WC500169714.pdf . Accessed 18 Mar 2015."},{"key":"398_CR7","unstructured":"Basilea Pharmaceutica. Basilea announces global partnership with Astellas for its antifungal isavuconazole (media release). 2010. http:\/\/www.basilea.com\/News-and-Media\/Basilea-announces-global-partnership-with-Astellas-for-its-antifungal-isavuconazole\/343 ."},{"key":"398_CR8","unstructured":"Basilea Pharmaceutica. Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America (media release). 2014. http:\/\/www.basilea.com\/News-and-Media\/Basilea-swaps-its-isavuconazole-North-American-co-promote-rights-for-full-isavuconazole-rights-outside-of-North-America\/c54f2a5d-f004-4aed-2d5c-d5f26ba841ae ."},{"issue":"5","key":"398_CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","volume":"170","author":"GR Thompson 3rd","year":"2010","unstructured":"Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170(5):291\u2013313.","journal-title":"Mycopathologia."},{"issue":"12","key":"398_CR10","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/AAC.01355-13","volume":"57","author":"AJ Lepak","year":"2013","unstructured":"Lepak AJ, Marchillo K, Vanhecker J, et al. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and CYP51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"398_CR11","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","volume":"57","author":"AJ Lepak","year":"2013","unstructured":"Lepak AJ, Marchillo K, VanHecker J, et al. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother. 2013;57(11):5642\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"398_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/dkn431","volume":"63","author":"J Majithiya","year":"2009","unstructured":"Majithiya J, Sharp A, Parmar A, et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother. 2009;63(1):161\u20136.","journal-title":"J Antimicrob Chemother."},{"issue":"8","key":"398_CR13","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","volume":"53","author":"PA Warn","year":"2009","unstructured":"Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009;53(8):3453\u201361.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"398_CR14","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","volume":"58","author":"G Luo","year":"2014","unstructured":"Luo G, Gebremariam T, Lee H, et al. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother. 2014;58(4):2450\u20133.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"398_CR15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","volume":"50","author":"A Schmitt-Hoffmann","year":"2006","unstructured":"Schmitt-Hoffmann A, Roos B, Maares J, et al. Mulitple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286\u201393.","journal-title":"Antimicrob Agents Chemother."},{"key":"398_CR16","unstructured":"Schmitt-Hoffmann A, Roos B, Spickermann J, et al. No relevant food effects in man on isavuconazole oral pharmacokinetics preliminary data (abstract no. A-008). In: 48th interscience conference on antimicrobial agents and chemotherapy\/Infectious Diseases Society of America 46th annual meeting. 2008."},{"issue":"1","key":"398_CR17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","volume":"50","author":"A Schmitt-Hoffmann","year":"2006","unstructured":"Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100. and 200 milligrams) and oral administrations (100, 200, and 400\u00a0milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279\u201385.","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"398_CR18","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.00319-09","volume":"53","author":"A Schmitt-Hoffmann","year":"2009","unstructured":"Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53(11):4885\u201390.","journal-title":"Antimicrob Agents Chemother."},{"key":"398_CR19","unstructured":"Yamazaki T, Pearlman H, Kowalski DL, et al. Effect of multiple doses of ketoconazole on the pharmacokinetics of isavuconazole in healthy subjects (abstract no. A-695). In: 54th interscience conference on antimicrobial agents and chemotherapy. 2014."},{"key":"398_CR20","unstructured":"Yamazaki T, Desai A, Kowalski D. Pharmacokinetic (PK) interaction between isavuconazole (ISA) and a fixed-dose combination of lopinavir [LPV] 400 mg\/ritonavir [RTV] 100\u00a0mg in healthy subjects (abstract no. 722). In: IDWeek. 2013."},{"issue":"Suppl 1","key":"398_CR21","first-page":"S90","volume":"95","author":"R Townsend","year":"2014","unstructured":"Townsend R, Yamazaki T, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of oral contraceptive with ethinyl estradiol and norethindrone in healthy subjects [abstract no. PII-088]. Clin Pharmacol Ther. 2014;95(Suppl 1):S90\u20131.","journal-title":"Clin Pharmacol Ther."},{"key":"398_CR22","first-page":"S39","volume":"93","author":"A Desai","year":"2013","unstructured":"Desai A, Zadeikis N, Howieson C, et al. Isavuconazole does not affect prednisolone pharmacokinetics in healthy subjects following coadministration of multiple dose isavuconazole. Clin Pharmacol Ther. 2013;93:S39.","journal-title":"Clin Pharmacol Ther."},{"key":"398_CR23","unstructured":"Desai A, Pearlman H, Yamazaki T, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP1A2 substrate caffeine and CYP2C8 substrate repaglinide in healthy subjects (abstract no. A-696). In: 54th interscience conference on antimicrobial agents and chemotherapy. 2014."},{"key":"398_CR24","unstructured":"Desai A, Yamazaki T, Lademacher C, et al. Effect of multiple doses of isavuconzole on the pharmacokinetics of methadone in healthy subjects (abstract no. R6335). In: American Association of Pharmaceutical Scientists annual meeting. 2013."},{"key":"398_CR25","unstructured":"Yamazaki T, Pearlman H, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate atorvastatin in healthy subjects (abstract no. A-449). In: 52nd interscience conference on antimicrobial agents and chemotherapy. 2012."},{"key":"398_CR26","unstructured":"Desai A, Yamazaki T, Lademacher C, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP2D6 substrate dextromethorphan in healthy subjects (abstract no. R6334). In: American Association of Pharmaceutical Scientists annual meeting. 2013."},{"key":"398_CR27","unstructured":"Desai A, Zadeikis N, Pearlman H. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate midazolam in healthy volunteers (abstract no. A-1936). In: 52nd interscience conference on antimicrobial agents and chemotherapy. 2012."},{"key":"398_CR28","first-page":"S114","volume":"93","author":"T Yamazaki","year":"2013","unstructured":"Yamazaki T, Zadeikis N, Pearlman H, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of sirolimus in healthy subjects. Clin Pharmacol Ther. 2013;93:S114.","journal-title":"Clin Pharmacol Ther."},{"key":"398_CR29","first-page":"S39","volume":"93","author":"A Desai","year":"2013","unstructured":"Desai A, Zadeikis N, Pearlman H, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate tacrolimus in healthy subjects. Clin Pharmacol Ther. 2013;93:S39\u201340.","journal-title":"Clin Pharmacol Ther."},{"key":"398_CR30","unstructured":"Desai A, Pearlman H, Yamazaki T, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP2B6 substrate bupropion in healthy subjects (abstract no. A-450). In: 53rd interscience conference on antimicrobial agents and chemotherapy. 2013."},{"issue":"Suppl 2","key":"398_CR31","first-page":"227","volume":"26","author":"R Townsend","year":"2013","unstructured":"Townsend R, Desai A, Howieson C, et al. Clinical considerations for coadministration of the novel antifungal isavuconazole with immunosuppressive agents (abstract no. P199). Transplant Int. 2013;26(Suppl 2):227.","journal-title":"Transplant Int."},{"key":"398_CR32","first-page":"S40","volume":"93","author":"A Desai","year":"2013","unstructured":"Desai A, Zadeikis N, Breese N, et al. Isavuconazole does not significantly affect the pharmacokinetics of p-glycoprotein substrate digoxin in healthy subjects. Clin Pharmacol Ther. 2013;93:S40.","journal-title":"Clin Pharmacol Ther."},{"key":"398_CR33","unstructured":"Desai A, Yamazaki T, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of metformin in healthy subjects (abstract no. PI-072). Clin Pharmacol Ther. 2014;95(Suupl 1):S41."},{"issue":"Suppl 1","key":"398_CR34","first-page":"S93","volume":"95","author":"T Yamazaki","year":"2014","unstructured":"Yamazaki T, Desai A, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of methotrexate in healthy subjects (abstract no. PII-095). Clin Pharmacol Ther. 2014;95(Suppl 1):S93.","journal-title":"Clin Pharmacol Ther."},{"key":"398_CR35","unstructured":"Maertens J, Patterson T, Rahav G, et al. A phase 3 randomised, double-blind trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE) (abstract no. O230a). In: 24th European Congress of Clinical Microbiology and Infectious Diseases. 2014."},{"key":"398_CR36","unstructured":"Thompson GR, Rendon A, Santos R, et al. Outcomes in patients with invasive fungal disease caused by dimorphic fungi treated with isavuconazole: experience from the VITAL trial (abstract no. M-1775). In: 54th Interscience Conference On Antimicrobial Agents And Chemotherapy. 2014."},{"key":"398_CR37","unstructured":"Queiroz-Telles F, Cornely OA, Perfect J, et al. Successful outcomes in patients with invasive fungal disease due to C. gattii and C. neoformans treated with isavuconazole: experience from the VITAL trial (abstract no. M-1773). In: 54th interscience conference on antimicrobial agents and chemotherapy. 2014."},{"issue":"3","key":"398_CR38","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.04586-14","volume":"59","author":"J Viljoen","year":"2015","unstructured":"Viljoen J, Azie N, Schmitt-Hoffmann AH, et al. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother. 2015;59(3):1671\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"398_CR39","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","volume":"59","author":"OA Cornely","year":"2015","unstructured":"Cornely OA, Bohme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078\u201385.","journal-title":"Antimicrob Agents Chemother."},{"key":"398_CR40","unstructured":"Basilea Pharmaceutica. Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study (media release). 2014. http:\/\/www.basilea.com ."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0398-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0398-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0398-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:42Z","timestamp":1559490102000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0398-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,23]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0398-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,23]]}}}